| Pertuzumab studied in …STUDIED_INderived200 of 239show all (up to 200) |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 239 trials list this drug (106 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390427Phase 1 · completed Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03716180Phase 1 · active not recruiting DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · 239 trials list this drug (106 active) | — | — | Early Stage HER2-Positive Breast Carcinoma,Early Stage Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04208178Phase 3 · active not recruiting Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07679269Phase 2 · not yet recruiting Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04266249Phase 2 · active not recruiting CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy · 239 trials list this drug (106 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03006172Phase 1 · active not recruiting To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer · 239 trials list this drug (106 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876714Phase 3 · recruiting ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07797218Phase 3 · recruiting Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07795424Phase 2 · not yet recruiting Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00781612Phase 2 · active not recruiting A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05150691Phase 1/Phase 2 · recruiting A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03644186Phase 2 · completed To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06891833Phase 2/Phase 3 · recruiting A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07102381Phase 2 · recruiting A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03417544Phase 2 · completed Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441890Phase 2 · recruiting BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07772245Phase 2 · not yet recruiting Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04158258completed A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01937117Phase 2 · active not recruiting Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02320435Phase 3 · active not recruiting A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial · 239 trials list this drug (106 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05113251Phase 3 · active not recruiting Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06439693Phase 2 · recruiting The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04784715Phase 3 · active not recruiting Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06136897Phase 2 · active not recruiting Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) · 239 trials list this drug (106 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07196774Phase 3 · active not recruiting A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03304080Phase 1/Phase 2 · active not recruiting Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06445400Phase 2 · active not recruiting A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02252887Phase 2 · completed Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07683754Phase 3 · not yet recruiting T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07716046Phase 2 · not yet recruiting Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07386938Phase 3 · active not recruiting A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03747120Phase 2 · active not recruiting Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06747338Phase 3 · active not recruiting A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05323955Phase 2 · active not recruiting Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04188548Phase 1 · active not recruiting A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01730833Phase 2 · completed Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma,Breast Inflammatory Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518173Phase 3 · recruiting A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03199885Phase 3 · terminated Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05582499Phase 2 · recruiting Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,Early Stage Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07610720Phase 2 · recruiting Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07612215Phase 1/Phase 2 · recruiting Elacestrant in Advanced Triple Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07578116Phase 3 · not yet recruiting Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis · 239 trials list this drug (106 active) | — | — | Oligometastatic Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04588545Phase 1/Phase 2 · active not recruiting Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease · 239 trials list this drug (106 active) | — | — | Leptomeningeal Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03125928Phase 2 · active not recruiting Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06686394Phase 1/Phase 2 · recruiting Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009) · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04329065Phase 2 · recruiting Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05319873Phase 1/Phase 2 · active not recruiting Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Invasive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07220135Phase 2 · recruiting Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07565324Phase 2 · not yet recruiting Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial) · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07402473Phase 2 · recruiting Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545044Phase 2 · not yet recruiting A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03820141Phase 2 · active not recruiting Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02326974Phase 2 · active not recruiting T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07527806Phase 2 · not yet recruiting Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07528898Phase 2 · not yet recruiting Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07441460Phase 3 · recruiting A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07371585Phase 2 · recruiting Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07335081Phase 2 · recruiting ctDNA in HER2+ EBC Neoadjuvant Treatment · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253561Phase 1 · completed Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07470203not yet recruiting Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05325632Phase 2 · recruiting Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07421141Phase 2 · active not recruiting De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07377643Phase 3 · recruiting IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04024462Phase 3 · completed A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06348134Phase 2 · recruiting Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02947685Phase 3 · active not recruiting Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03101748Phase 1/Phase 2 · terminated Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03365882Phase 2 · completed S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery · 239 trials list this drug (106 active) | — | — | Colon Adenocarcinoma,Colon Carcinoma,Malignant Colon Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05415215Phase 3 · completed A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07393425Phase 2 · recruiting Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01796197Phase 2 · completed Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06771622Phase 1/Phase 2 · active not recruiting Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · 239 trials list this drug (106 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02057133Phase 1 · active not recruiting A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07340398Phase 2 · recruiting Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04538742Phase 1/Phase 2 · active not recruiting A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05786716Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations · 239 trials list this drug (106 active) | — | — | Skin Neoplasm,Solid Neoplasm,Lung Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05180006Phase 2 · terminated Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01358877Phase 3 · completed A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07246317Phase 2 · not yet recruiting Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04193059Phase 3 · active not recruiting Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04514419Phase 3 · active not recruiting Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954143Phase 2 · terminated Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 239 trials list this drug (106 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04425018Phase 2 · active not recruiting MARGetuximab Or Trastuzumab (MARGOT) · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05041842Phase 2 · active not recruiting Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02827877Phase 2 · active not recruiting Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04419181Phase 2 · withdrawn Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06884254Phase 3 · withdrawn Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108858Phase 1/Phase 2 · terminated Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06178159Phase 2 · recruiting DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264547Phase 3 · completed A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07187752NA · not yet recruiting Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05385705Phase 1 · terminated A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514681Phase 3 · completed A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900206Phase 2 · recruiting Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06490536Phase 3 · recruiting The Sagittarius Trial · 239 trials list this drug (106 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07116824Phase 2 · not yet recruiting HB1801 Combined Treatment of HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02003209Phase 3 · completed Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02205047Phase 2 · completed Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma · 239 trials list this drug (106 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07093931Phase 4 · not yet recruiting Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05802225Phase 3 · active not recruiting Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02436993Phase 2 · active not recruiting Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab · 239 trials list this drug (106 active) | — | — | Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07047755Phase 2 · not yet recruiting Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06927180Phase 2 · recruiting SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05346224Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05838066Phase 3 · recruiting Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer. · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03161353Phase 2 · active not recruiting Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04680442Phase 2 · recruiting Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020860Phase 2 · recruiting Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01817452Phase 2 · completed A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02625441Phase 3 · active not recruiting Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551521Phase 2 · completed CRAFT: The NCT-PMO-1602 Phase II Trial · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05891561Phase 2 · recruiting Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02339532Phase 2 · completed Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03726879Phase 3 · completed A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05426486Phase 2/Phase 3 · active not recruiting A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04957212Phase 3 · completed Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02091141Phase 2 · completed My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors · 239 trials list this drug (106 active) | — | — | Neoplasm,Solid Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06510465Phase 2 · not yet recruiting Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA) · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05283837Phase 3 · completed A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03493854Phase 3 · completed A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02344472Phase 3 · unknown Detect V / CHEVENDO (Chemo vs. Endo) · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02291289Phase 2 · completed A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) · 239 trials list this drug (106 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04629846Phase 3 · completed Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03595592Phase 3 · active not recruiting Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Invasive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01120184Phase 3 · completed A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE) · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 239 trials list this drug (106 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05574881Phase 1/Phase 2 · unknown Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06278870Phase 3 · recruiting Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159193Phase 3 · recruiting Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 239 trials list this drug (106 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06162559Phase 1 · recruiting Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03674112Phase 2 · completed A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04197687Phase 2 · unknown TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Breast Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05978648Phase 2 · recruiting Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04172259Phase 2 · active not recruiting ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05912062unknown Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03329378Phase 2 · terminated Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05983094Phase 2 · not yet recruiting Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05883852Phase 3 · recruiting EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02586025Phase 3 · completed Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03988036Phase 2 · completed A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1) · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01922921Phase 1/Phase 2 · completed Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05036005Phase 4 · unknown Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON) · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05638594Phase 2 · recruiting Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412643Phase 2 · unknown Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05738993Phase 1 · unknown A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05720026Phase 3 · unknown Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05656079NA · unknown To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02229149Phase 2 · terminated Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05420454Phase 4 · recruiting A Study for the Neoadjuvant Treatment of Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05420467Phase 4 · recruiting A Study for the Adjuvant Treatment of Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05188313Phase 3 · recruiting TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer · 239 trials list this drug (106 active) | — | — | Malignant Esophageal Neoplasm,Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05429684Phase 3 · unknown Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01966471Phase 3 · completed A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02789657Phase 2 · completed Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01904903Phase 2 · completed Cardiac Safety Study in Patients With HER2 + Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04398914Phase 2 · active not recruiting Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02896855Phase 3 · completed A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536339Phase 2 · completed A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05131893not yet recruiting Neoadjuvant Treatment of Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01850628unknown NSABP Biospecimen Discovery Project · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03894007Phase 2 · terminated Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer · 239 trials list this drug (106 active) | — | — | Early Stage Breast Carcinoma,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02073487Phase 2 · completed Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02132949Phase 2 · completed A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01847001Phase 2 · completed Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy · 239 trials list this drug (106 active) | — | — | Malignant Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03135171Phase 1 · completed Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04993014Phase 2 · recruiting Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04717531Phase 2 · unknown Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04760431Phase 2 · unknown TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) · 239 trials list this drug (106 active) | — | — | Brain Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02266173completed Observational Study of Pertuzumab Safety in Participants With Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01835236Phase 2 · completed Trastuzumab & Pertuzumab Followed by T-DM1 in MBC · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02139358Phase 1/Phase 2 · completed Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682693Phase 2 · completed Denosumab as an add-on Neoadjuvant Treatment (GeparX) · 239 trials list this drug (106 active) | — | — | Breast Inflammatory Carcinoma,Breast Mucinous Carcinoma,Breast Tubular Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02336984Phase 1/Phase 2 · withdrawn A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01774786Phase 3 · completed A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer · 239 trials list this drug (106 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04683445unknown Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01491737Phase 2 · completed A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03144947Phase 2 · unknown Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01572038Phase 3 · completed A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01875666early Phase 1 · completed Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530424Phase 2 · completed "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04337658Phase 3 · unknown Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01855828Phase 2 · completed Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02605915Phase 1 · completed Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer · 239 trials list this drug (106 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00567190Phase 3 · completed A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03811418Phase 3 · withdrawn A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02445586Phase 4 · completed Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02402712Phase 3 · completed Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02131064Phase 3 · completed A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00833963completed A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03058939Phase 2 · withdrawn Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959490Phase 2 · completed Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01912963Phase 2 · terminated Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer · 239 trials list this drug (106 active) | — | — | Malignant Breast Neoplasm,HER2-Positive Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02689921Phase 2 · unknown NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer · 239 trials list this drug (106 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |